Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.93 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.93 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.66 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.66 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.64 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.64 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.64 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360770 | 0.96 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6432237 | 0.96 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6433051 | 0.96 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL343164 | 0.90 | ITGAV (0.76) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6431919 | 0.87 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6431924 | 0.87 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6434481 | 0.86 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6432359 | 0.86 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6432362 | 0.86 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL6437606 | 0.86 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB8ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1044001-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-07-06 | — | — | EP | claimed |
| US-6211191-B1 | TETRAHYDROPYRIMIDIN-2-ONE DERIVATIVES; BONE DISORDERS, OSTEOPOROSIS, RESTENOSIS, VISION DEFECTS; ANGIOGENESIS INHIBITORS; ANTITUMOR, ANTIARTHRITIC, ANTICARCINOGENIC, AND ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-04-03 | — | — | US | claimed |
| EP-2155769-B1 | TISSUE DEGENERATION PROTECTION | UNIV LEUVEN KATH (BE) | 2012-06-27 | — | — | EP | disclosed |
| EP-2398472-A2 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS WITH A POLYAMINE (E.G. SPERMINE, SPERMIDINE) | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010081862-A2 | METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-07-22 | — | — | WO | disclosed |
| US-20080249016-A1 | Use of GLP-2 in a combination treatment for bone-related disorders | SANOS BIOSCIENCE A/S | 2008-10-09 | — | — | US | disclosed |
| US-20070135345-A1 | Use of GLP-2 for the treatment or prevention, of bone-related disorders | SANOS BIOSCIENCE A/S (DK) | 2007-06-14 | — | — | US | disclosed |
| US-7186683-B2 | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders | SANOS BIOSCIENCE A/S (DK) | 2007-03-06 | — | — | US | disclosed |
| US-20050282749-A1 | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes | SANOS BIOSCIENCE A/S | 2005-12-22 | — | — | US | disclosed |
| EP-1044001-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040052862-A1 | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders | SANOS BIOSCIENCE A/S (DE) | 2004-03-18 | — | — | US | disclosed |
| US-20020037836-A1 | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders | SANOS BIOSCIENCE A/S (DK) | 2002-03-28 | — | — | US | disclosed |
| US-6211191-B1 | TETRAHYDROPYRIMIDIN-2-ONE DERIVATIVES; BONE DISORDERS, OSTEOPOROSIS, RESTENOSIS, VISION DEFECTS; ANGIOGENESIS INHIBITORS; ANTITUMOR, ANTIARTHRITIC, ANTICARCINOGENIC, AND ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-04-03 | — | — | US | disclosed |